Cellectis SA

Company Profile

Cellectis SA had its IPO on 2007-02-07 under the ticker symbol CLLS.

The company operates in the Healthcare sector and Biotechnology industry. Cellectis SA has a staff strength of 0 employees.

Stock update

Shares of Cellectis SA opened at $1.8 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $1.8 - $1.89, and closed at $1.88.

This is a +1.08% increase from the previous day's closing price.

A total volume of 74,500 shares were traded at the close of the day’s session.

In the last one week, shares of Cellectis SA have slipped by -9.4%.

Cellectis SA's Key Ratios

Cellectis SA has a market cap of $112.04 million, indicating a price to book ratio of 0.7503 and a price to sales ratio of 4.4785.

In the last 12-months Cellectis SA’s revenue was $25.72 million with a gross profit of $23.95 million and an EBITDA of $-78507336. The EBITDA ratio measures Cellectis SA's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cellectis SA’s operating margin was -348.57% while its return on assets stood at -17.42% with a return of equity of -54.46%.

In Q3, Cellectis SA’s quarterly earnings growth was a positive 0% while revenue growth was a positive 26.8%.

Cellectis SA’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-1.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cellectis SA’s profitability.

Cellectis SA stock is trading at a EV to sales ratio of 5.0715 and a EV to EBITDA ratio of -0.6403. Its price to sales ratio in the trailing 12-months stood at 4.4785.

Cellectis SA stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$279.58 million

Total Liabilities

$53.03 million

Operating Cash Flow

$-61000.00

Capital Expenditure

$622000

Dividend Payout Ratio

0%

Cellectis SA ended 2023 with $279.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $279.58 million while shareholder equity stood at $136.64 million.

Cellectis SA ended 2023 with $0 in deferred long-term liabilities, $53.03 million in other current liabilities, 2949000.00 in common stock, $-409921000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $119.01 million and cash and short-term investments were $119.01 million. The company’s total short-term debt was $18,350,000 while long-term debt stood at $14.70 million.

Cellectis SA’s total current assets stands at $140.27 million while long-term investments were $8.93 million and short-term investments were $0. Its net receivables were $12.95 million compared to accounts payable of $22.35 million and inventory worth $0.

In 2023, Cellectis SA's operating cash flow was $-61000.00 while its capital expenditure stood at $622000.

Comparatively, Cellectis SA paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$1.88

52-Week High

$5.04

52-Week Low

$1.8

Analyst Target Price

$10.1

Cellectis SA stock is currently trading at $1.88 per share. It touched a 52-week high of $5.04 and a 52-week low of $5.04. Analysts tracking the stock have a 12-month average target price of $10.1.

Its 50-day moving average was $2.61 and 200-day moving average was $2.67 The short ratio stood at 1.92 indicating a short percent outstanding of 0%.

Around 1213% of the company’s stock are held by insiders while 1657.9% are held by institutions.